Dong Jae Baek
Overview
Explore the profile of Dong Jae Baek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
286
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Limbu K, Chhetri R, Kim S, Shrestha J, Oh Y, Baek D, et al.
Cancer Cell Int
. 2024 Oct;
24(1):353.
PMID: 39462385
Pancreatic cancer is known to be the most lethal cancer. Fewer new treatments are being developed for pancreatic cancer as compared to other cancers. The bioactive lipid S1P, which is...
2.
Shrestha J, Limbu K, Chhetri R, Paudel K, Hansbro P, Oh Y, et al.
Int J Biol Sci
. 2024 Sep;
20(12):4888-4907.
PMID: 39309448
Reactive oxygen species are involved in the pathogenesis of cancers and metabolic diseases, including diabetes, obesity, and fatty liver disease. Thus, inhibiting the generation of free radicals is a promising...
3.
Baek J, Lee J, Kim J, Cho S, Kim Y, Yang J, et al.
Biochem Pharmacol
. 2024 Sep;
229:116520.
PMID: 39236934
Hepatic stellate cells (HSCs) play a role in hepatic fibrosis and sphingosine kinase (SphK) is involved in biological processes. As studies on the regulatory mechanisms and functions of SphK in...
4.
Limbu K, Chhetri R, Oh Y, Baek D, Park E
Molecules
. 2022 Dec;
27(23).
PMID: 36500220
Pancreatic ductal adenocarcinoma (PDAC) has one of the highest mortality rates and requires the development of highly efficacious medications that can improve the efficiency of existing treatment methods. In particular,...
5.
Kim S, Limbu K, Oh Y, Kim S, Park S, Baek D, et al.
Pharmaceutics
. 2022 Oct;
14(10).
PMID: 36297469
Lung cancer can be divided into non-small cell lung cancer (NSCLC) and small cell lung cancer, and the incidence and mortality rate are continuously increasing. In many cases, lung cancer...
6.
Kim K, Park E, Baek D, Oh Y
Food Sci Biotechnol
. 2022 Aug;
31(10):1289-1297.
PMID: 35992315
Supplementary Information: The online version contains supplementary material available at 10.1007/s10068-022-01117-9.
7.
Kim S, Oh Y, Kim K, Cho S, Park S, Baek D, et al.
Molecules
. 2022 May;
27(10).
PMID: 35630821
Sphingosine kinase (SK) is involved in the growth of cells, including cancer cells. However, which of its two isotypes-SK1 and SK2-is more favorable for cancer growth remains unclear. Although PF-543...
8.
Shrestha J, Kim S, Kim S, Oh Y, Ki S, Lee T, et al.
Pharmaceutics
. 2022 Jan;
14(1).
PMID: 35057052
Sphingosine kinase (SK) enzyme, a central player of sphingolipid rheostat, catalyzes the phosphorylation of sphingosine to the bioactive lipid mediator sphingosine 1 phosphate (S1P), which regulates cancer cell proliferation, migration,...
9.
Shrestha J, Shamshiddinova M, Lee Y, Oh Y, Baek D, Park E
Curr Mol Pharmacol
. 2021 Aug;
15(3):570-581.
PMID: 34382511
Background And Objective: Colorectal cancer (CRC) is the fourth leading cause of cancer- related death globally, with a high incidence rate in economically fast-growing countries. Sphingosine- 1-phosphate (S1P) is a...
10.
Yoon M, Lee Y, Park C, Hong J, Baek D, Shin D
Arch Pharm Res
. 2020 Oct;
43(10):1046-1055.
PMID: 33111965
Fingolimod has been evaluated for use as an anticancer agent. However, many steps are required to synthesize fingolimod because of its intricate structure. A fingolimod analogue, N-(4-(2-((4-methoxybenzyl)amino)ethyl)phenyl)heptanamide (MPH), also has...